Neurofeedback Using Implanted Deep Brain Stimulation Electrodes

Launched by ETH ZURICH · Oct 19, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to treating conditions like Parkinson's disease, epilepsy, and essential tremor using a method called neurofeedback with a special device called the Percept™ PC neurostimulator. This device not only helps control symptoms by sending electrical signals to the brain but also allows doctors to measure brain activity. The goal is to see if patients can learn to control their brain activity in real-time, which could lead to better management of their symptoms over time.

To be eligible for the trial, participants must be at least 18 years old and need to have the Percept™ PC neurostimulator implanted for medical reasons, with a planned hospital stay of at least three days afterward. Participants can expect to engage in training sessions where they will receive feedback on their brain activity, helping them to learn how to reduce unwanted brain signals associated with their condition. Importantly, the risks to participants are minimal, as the changes in brain activity are self-induced and the device will not affect the usual stimulation settings during the trial. This research could lead to new and effective treatment options for various neurological disorders.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients undergoing clinically indicated implantation of a Percept™ PC neurostimulator, age ≥ 18 years as well as planned hospitalisation of ≥ 3 days after operation
• Exclusion Criteria:
• • minimal prognosticated survival of less than 1 year, reduced state of consciousness (i. e. Glasgow Coma Scale \< 15), inability to communicate (in terms of hearing, seeing, speaking and understanding), other significant concomitant diseases (e. g. cardiovascular disease, infectious disease, isolation), inability to follow procedures, insufficient knowledge of project language, inability to give consent and unlikeliness to follow protocol.